CεmX domain of membrane-bound IgE (mIgE)

Class

anti-CεmX humanized monoclonal antibody (IgG1)

Pathway

binds mIgE on IgE+ B lymphocytes, depleting them via ADCC/apoptosis without binding secreted IgE

Membrane-bound IgE (mIgE) is the form of the antibody immunoglobulin E that sits on the surface of certain B lymphocytes before those cells mature into plasma cells that secrete free IgE into the bloodstream. Free IgE is central to allergic disease: it binds high-affinity receptors on mast cells and basophils, priming them to release histamine and other mediators on exposure to an allergen. Membrane IgE carries a short extracellular segment, called the CεmX domain, that is absent from the secreted form. Antibodies engineered to recognize CεmX therefore bind selectively to IgE-producing B cells rather than to circulating IgE itself. Once bound, these antibodies can flag the B cells for destruction through antibody-dependent cellular cytotoxicity, in which immune effector cells kill the tagged target, or through direct induction of programmed cell death. The rationale is to reduce the population of cells capable of making IgE, rather than only neutralizing IgE already in circulation. This approach is relevant to allergic conditions such as asthma, atopic dermatitis, and allergic rhinitis, where chronic IgE production sustains disease activity, and it represents a mechanistically distinct complement to therapies that act on free IgE or its receptors.